ArticlebioRxiv : the preprint server for biology2024
The atypical antipsychotic aripiprazole alters the outcome of disseminated
Parker Reitler, Jessica Regan, Christian DeJarnette, Ashish Srivastava, Jen Carnahan, Katie M Tucker, Bernd Meibohm, Brian M Peters, Glen E Palmer
Open access · greenAbstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors at 1 institution in 1 country.
Parker ReitlerIntegrated Program in Biomedical Sciences, College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Jessica ReganPharmaceutical Sciences Program, College of Graduate Health Sciences, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Christian DeJarnetteDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Ashish SrivastavaDepartment of Pharmaceutical Sciences College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Jen CarnahanDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Katie M TuckerDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Bernd MeibohmDepartment of Pharmaceutical Sciences College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.ORCID 0000-0003-3923-3648 Brian M PetersDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.ORCID 0000-0002-0445-2077 Glen E PalmerDepartment of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.ORCID 0000-0003-4083-3130 University of Tennessee Health Science Center · US
Funding
Antifungal antagonism as a cause of treatment failure for invasive mycosesR01AI152067 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PALMER, GLEN · 2021 to 2025
$3.1MCandidalysin: a key mediator of Candida vaginitis immunopathologyR01AI134796 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI Brian M Peters · 2018 to 2026
$2.9MBroad spectrum antifungals targeting fatty acid biosynthesisR33AI127607 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI PALMER, GLEN · 2019 to 2022
$1.5MNIAID NIH HHS R01 AI134796NIAID NIH HHS R01 AI152067NIAID NIH HHS R33 AI127607
6 · The paper itselfAbstract
Invasive fungal infections (IFIs) impose an enormous clinical, social, and economic burden on humankind. For many IFIs, ≥ 30% of patients fail therapy with existing antifungal drugs, including the widely used azole class. We previously identified a collection of 13 approved medications that antagonize azole activity. While gain-of-function mutants resulting in antifungal resistance are often associated with reduced fitness and virulence, it is currently unknown how exposure to azole antagonistic drugs impact
Identifiers
PMID38405954
PMCPMC10888916
OpenAlexW4391838095
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390